Guangdong Taienkang Pharmaceutical Co Ltd (301263)

Currency in CNY
34.52
-0.47(-1.34%)
Closed·

301263 Financial Summary

Key Ratios

P/E Ratio248.41
Price/Book7.79
Debt / Equity19.15%
Return on Equity2.8%
Dividend Yield0.57%
EBITDA162.46M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2022
01/01
2023
01/01
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.15%
Dividend Yield
0.57%
Industry Median 1.47%
Annualised payout
0.20
Paid annually
5-Years Growth
-11.15%
Growth Streak

Earnings

Latest Release
Aug 21, 2025
EPS / Forecast
0.01 / --
Revenue / Forecast
162.42M / --
EPS Revisions
Last 90 days

FAQ

What were Guangdong Taienkang Pharmaceutical's earnings for the latest quarter?

The Guangdong Taienkang Pharmaceutical EPS (TTM) is 0.15. Guangdong Taienkang Pharmaceutical reported sales of 162.42, net income of 5.54, and EPS of 0.01 for the latest quarter.

What was Guangdong Taienkang Pharmaceutical's net income for the latest quarter?

Guangdong Taienkang Pharmaceutical's net income for the latest quarter was 5.54.

How did Guangdong Taienkang Pharmaceutical's performance compare year-over-year in the latest quarter?

The company's revenue moved from 184.66 in the previous quarter to 162.42 in the latest quarter, and net income moved from 31.55 to 5.54 compared to the previous quarter.

What is Guangdong Taienkang Pharmaceutical's net profit margin on a TTM basis?

Guangdong Taienkang Pharmaceutical's trailing twelve months (TTM) net profit margin is 15.01%.

How does Guangdong Taienkang Pharmaceutical's debt to equity ratio compare to industry standards?

Guangdong Taienkang Pharmaceutical's total debt-to-equity ratio is 19.15%.

What is Guangdong Taienkang Pharmaceutical's return on investment on a TTM basis?

Guangdong Taienkang Pharmaceutical's trailing twelve months (TTM) return on investment (ROI) is 2.80%.

Did Guangdong Taienkang Pharmaceutical gain or lose cash last quarter?

In the latest quarter, Guangdong Taienkang Pharmaceutical's net change in cash was 234.06 million.

What were Guangdong Taienkang Pharmaceutical's total assets and liabilities in the latest quarter?

As of the latest quarter, Guangdong Taienkang Pharmaceutical reported total assets of 2,508.43 million and total liabilities of 584.79 million.

How has Guangdong Taienkang Pharmaceutical's total revenue grown this year?

Guangdong Taienkang Pharmaceutical's total revenue was 184.66 in the previous quarter and 162.42 in the latest quarter.

What is Guangdong Taienkang Pharmaceutical's gross margin on a TTM basis?

Guangdong Taienkang Pharmaceutical's trailing twelve months (TTM) gross margin is 51.75%.

What was Guangdong Taienkang Pharmaceutical's revenue per share for the latest quarter?

Guangdong Taienkang Pharmaceutical's revenue per share for the latest quarter was 6.55.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.